Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line

Full text
Author(s):
Borges, Kleiton S. ; Andrade, Augusto F. ; Silveira, Vanessa S. ; Marco Antonio, David S. ; Vasconcelos, Elton J. R. ; Antonini, Sonir R. R. ; Tone, Luiz G. ; Scrideli, Carlos A.
Total Authors: 8
Document type: Journal article
Source: ANTI-CANCER DRUGS; v. 28, n. 6, p. 634-644, JUL 2017.
Web of Science Citations: 8
Abstract

Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar results were also reported for adult ACTs. The present in-vitro study shows that AMG 900 inhibits aurora kinases in adrenocortical carcinoma cells. AMG 900 inhibited cell proliferation in NCI-H295 cells as well as in the ACT primary cultures and caused apoptosis in the cell line NCI-H295. Furthermore, it potentialized the mitotane, doxorubicin, and etoposide effects on apoptosis induction and acted synergistically with mitotane and doxorubicin in the inhibition of proliferation. In addition, we found that AMG 900 activated Notch signaling and rendered the cells sensitive to the combination of AMG 900 and Notch signaling inhibition. Altogether, these data show that aurora kinases inhibition using AMG 900 may be an adjuvant therapy to treat patients with invasive or recurrent adrenocortical carcinomas. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved. (AU)

FAPESP's process: 10/07020-9 - Molecular studies in neoplasias of children and adolescents: microRNAs signature and functional studies of candidate genes to target therapy
Grantee:Carlos Alberto Scrideli
Support type: Regular Research Grants
FAPESP's process: 10/08699-5 - Mechanisms involved in the inhibition of aurora-kinases in adrenal carcinoma
Grantee:Kleiton Silva Borges
Support type: Scholarships in Brazil - Doctorate